Friday, October 23, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Upgrades Oracle to Outperform with 159 Price Target

Elaine Mendonca by Elaine Mendonca
March 12, 2024
in Breaking News
0
Technology Robotics Trading online
0
SHARES
45
VIEWS
Share on FacebookShare on Twitter

Analyst Mark Moerdler from Bernstein is bullish on Oracle (NYSE:ORCL) as of March 12, 2024. He has upgraded the stock to Outperform and increased the price target to $159, citing a positive outlook for the company. Moerdler specifically praises Oracle’s advancements in cloud computing and generative AI, which have positioned them well in the market.

A consensus of 34 analysts also supports an Outperform rating for Oracle, with an average target price of $124.7 USD. Some analysts have noted similarities between Oracle and Microsoft in their cloud transition strategies and operating margins.

Oracle’s focus on customer choice and hybrid environments is seen as a strategic move to meet diverse needs and ensure customer success. This customer-centric approach has been a key factor in Oracle’s success in the market.

Oracle Corporation (ORCL) Stock Shows Strong Performance on March 12, 2024

On March 12, 2024, Oracle Corporation (ORCL) showed strong performance in the stock market, with the stock trading near the top of its 52-week range and above its 200-day simple moving average. This indicates positive price momentum for the company.

The price of ORCL shares increased by $1.71 since the market last closed, representing a 1.52% rise from the previous day’s closing price of $114.13. This uptick in price suggests that investors are feeling optimistic about the company’s prospects.

In pre-market trading, the stock continued to show impressive growth, with a further increase of $14.57.

Overall, ORCL’s stock performance on March 12, 2024, reflects strong investor confidence in the company. Investors will be closely watching to see if this momentum continues in the days ahead.

Oracle Corporation (ORCL) Reports Strong Financial Performance with 17.7% Revenue Increase

On March 12, 2024, Oracle Corporation (ORCL) saw a strong performance in terms of its financials. According to data from CNN Money, the tech giant reported total revenue of $49.95 billion for the past year, representing a 17.7% increase compared to the previous year. In the second quarter of the fiscal year, Oracle reported total revenue of $12.94 billion, showing a 3.92% increase from the previous quarter.

Similarly, Oracle’s net income also showed positive growth trends. The company reported a net income of $8.50 billion for the past year, marking a 26.59% increase compared to the previous year. In the second quarter, Oracle reported a net income of $2.50 billion, showing a 3.43% increase from the previous quarter.

Earnings per share (EPS) for Oracle also saw significant growth. The company reported an EPS of $3.07 for the past year, reflecting a 27.5% increase compared to the previous year. In the second quarter, Oracle reported an EPS of $0.89, showing a 3.65% increase from the previous quarter.

Tags: ORCL
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Healthcare-and-Tech

RBC Capital Analyst Initiates Coverage on DexCom with Positive Outlook and Unveils Groundbreaking OvertheCounter CGM

Bioventus Surges in Stock Prices with Impressive Q4 Results and Optimistic FY24 Forecast

Biotechnology Stock Bull Market

Kineta Inc Provides Promising Update on VISTA101 Trial for KVA12123 in Advanced Solid Tumor Patients

Recommended

BioNTech Stock

BioNTech Investors Face Legal Challenge Following CureVac Acquisition

10 months ago
Eli Lilly Stock

Eli Lilly Faces Pricing Pressure as New Regulations Force Strategic Shift

1 year ago
MMM stock news

WestPark Capital Downgrades Palo Alto Networks to Hold Rating Despite Companys Resolute Stance

3 years ago
Inmune Bio Stock

Inmune Bio Navigates Strategic Shift Amid Market Pressures

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Most Stocks Rose While the Index Fell: Earnings Week Is the Test

Tesla Jumps on a Roadster as Tech Slips Into the Weekend

CoreWeave’s Bonds Flash Red as Strong Earnings Fall Flat

Hot Core CPI Sorts the Stocks: ASML Delivers, J&J Stumbles

Goldman Delivers as Memory Stocks Slide Ahead of CPI

Optics Run Hot as Chip Leaders Pause for Breath

Trending

Bitcoin Stock
Newsletter

Lam, Tesla and Meta Clear the Bar and Still Get Sold

by Stephanie Dugan
October 22, 2026
0

Dear readers, Wednesday's open question got its answer overnight. Lam Research told investors that global spending on...

Danaher Stock

Beat Estimates, Lose Ground: Guidance Now Drives Earnings Season

October 21, 2026
Mastercard Stock

The AI Rally Needs Cheap Money, and Cheap Money Is Scarce

October 20, 2026
Meta Stock

Most Stocks Rose While the Index Fell: Earnings Week Is the Test

October 18, 2026
Tesla Stock

Tesla Jumps on a Roadster as Tech Slips Into the Weekend

October 16, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Lam, Tesla and Meta Clear the Bar and Still Get Sold
  • Beat Estimates, Lose Ground: Guidance Now Drives Earnings Season
  • The AI Rally Needs Cheap Money, and Cheap Money Is Scarce

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com